KREBS BIOCHEMICALS & INDUSTRIES
|
KREBS BIOCHEMICALS & INDUSTRIES Last 5 Year Financial Ratios History
[Standalone]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -7.85 | -12.49 | -9.15 | -11.45 | -20.65 |
| CEPS(Rs) | -4.87 | -9.39 | -6.01 | -8.41 | -17.73 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | -75.49 | -67.83 | -55.29 | -46.13 | -34.83 |
| Tax Rate(%) | - | -0.06 | - | - | - |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | -22.97 | -34.70 | -17.30 | -30.27 | -56.94 |
| EBIT Margin(%) | -41.49 | -48.51 | -29.83 | -41.66 | -65.55 |
| Pre Tax Margin(%) | -71.35 | -62.16 | -39.13 | -47.36 | -74.58 |
| PAT Margin (%) | -71.35 | -62.20 | -39.13 | -47.36 | -74.58 |
| Cash Profit Margin (%) | -44.29 | -46.75 | -25.71 | -34.78 | -64.03 |
| Performance Ratios | |||||
| ROA(%) | -10.19 | -15.52 | -11.17 | -13.54 | -25.51 |
| ROE(%) | - | - | - | - | - |
| ROCE(%) | -15.38 | -29.92 | -18.99 | -28.59 | -57.38 |
| Asset Turnover(x) | 0.14 | 0.25 | 0.29 | 0.29 | 0.34 |
| Sales/Fixed Asset(x) | 0.08 | 0.14 | 0.16 | 0.18 | 0.22 |
| Working Capital/Sales(x) | -0.23 | -0.46 | -1.14 | -1.58 | -1.40 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 13.23 | 7.23 | 6.10 | 5.67 | 4.60 |
| Receivable days | 0.42 | 8.23 | 8.79 | 4.91 | 3.60 |
| Inventory Days | 90.24 | 66.69 | 78.69 | 131.30 | 128.88 |
| Payable days | - | 1,219.44 | 948.90 | 378.02 | 263.51 |
| Valuation Parameters | |||||
| PER(x) | - | - | - | - | - |
| PCE(x) | -8.21 | -7.11 | -10.15 | -6.71 | -8.09 |
| Price/Book(x) | -0.53 | -0.98 | -1.10 | -1.22 | -4.12 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 13.10 | 8.22 | 6.45 | 5.85 | 7.57 |
| EV/Core EBITDA(x) | -90.82 | -24.86 | -39.30 | -20.11 | -13.77 |
| EV/EBIT(x) | -31.58 | -16.95 | -21.62 | -14.04 | -11.55 |
| EV/CE(x) | 5.01 | 5.40 | 4.37 | 3.63 | 2.38 |
| M Cap / Sales | 3.63 | 3.32 | 2.61 | 2.33 | 5.18 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -45.21 | -14.10 | -3.29 | -12.68 | 11.18 |
| Core EBITDA Growth(%) | 76.09 | -73.11 | 45.43 | 53.83 | -93.68 |
| EBIT Growth(%) | 53.13 | -39.70 | 30.76 | 44.50 | -77.25 |
| PAT Growth(%) | 37.14 | -36.55 | 20.10 | 44.55 | -57.01 |
| EPS Growth(%) | 37.14 | -36.55 | 20.10 | 44.55 | -42.89 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | -1.38 | -1.45 | -1.62 | -1.84 | -1.91 |
| Current Ratio(x) | 0.09 | 0.10 | 0.28 | 0.33 | 0.45 |
| Quick Ratio(x) | 0.03 | 0.04 | 0.12 | 0.08 | 0.13 |
| Interest Cover(x) | -1.39 | -3.55 | -3.21 | -7.30 | -7.26 |
| Total Debt/Mcap(x) | 2.61 | 1.47 | 1.47 | 1.51 | 0.46 |
Compare Financial Ratios of peers of KREBS BIOCHEMICALS & INDUSTRIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| KREBS BIOCHEMICALS & INDUSTRIES | ₹149.9 Cr | 18.2% | 27.1% | -20.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹434,280.0 Cr | -2.4% | -6.2% | 11.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹246,737.0 Cr | -3.3% | 1.4% | 57.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹181,129.0 Cr | -4.5% | -4% | 35.9% | Stock Analytics | |
| CIPLA | ₹108,808.0 Cr | -3.6% | -5% | -10.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,170.0 Cr | -0.2% | 2.5% | -3% | Stock Analytics | |
KREBS BIOCHEMICALS & INDUSTRIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| KREBS BIOCHEMICALS & INDUSTRIES | 18.2% |
27.1% |
-20.7% |
| SENSEX | -2.3% |
-6.6% |
-12% |
You may also like the below Video Courses
